Riduttasi

<p>Potent TR inhibitor with IC50: 3.3μM, also inhibits glutathione reductase (IC50: 64.8μM) and T. brucei (EC50: 1μM).</p>

Imirestat (HOE 843) is an aldose reductase inhibitor that can be used in diabetes research.

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR.

Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.Turosteride has antitumor activity for the treatment of oncologic diseases and

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM).

Trimethoprim (NSC-106568) inhibits dihydrofolate reductase, CYP2C8, and OCT2 - an antibacterial agent.

<p>Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.</p>

Epalrestat (ONO2235), an aldose reductase inhibitor, helps manage diabetic neuropathy symptoms and slows disease progression.

Alconil is a biochemical.

Fluvastatin sodium (Fluvastatin sodium salt), a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), is a commonly used cholesterol

MK 0434 is a steroid 5α-reductase inhibitor and hormone antagonist associated with a significant reduction in DHT.

<p>Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase.Cost-effective and quality-assured.</p>

ALR2-IN-1: potent, selective inhibitor of ALR2 (IC50=1.42 μM), antiglycemic, antioxidant; for diabetes research.

ALR2-IN-6 (compound 9) is a potent competitive inhibitor of ALR2, with a Ki value of 0.064 μM. It is applicable in research related to neuropathy, retinopathy, and nephropathy.

<p>DDHF20 is an inhibitor of Staphylococcus aureus, specifically targeting and inhibiting its thioredoxin reductase (TrxR) by acting as a competitive inhibitor at the NADPH binding site. DDHF20 shows potential for research in combating infections related to Staphylococcus aureus.</p>

Isomer-Turosteride, a novel 5α-reductase inhibitor, reduces prostate DHT and has anticancer properties without raising T levels.

Floramanoside C exhibits 2,2-diphenyl-1-picrylhydrazyl scavenging and aldose reductase inhibitory activities [1].

<p>1264 small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.</p>

Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.

AKR1Cs-IN-1 (Compound 29) is an effective and broad-spectrum inhibitor of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). It achieves subtype inhibition by simultaneously binding to the SP2 and SP3 pockets, thereby blocking metabolic pathways related to drug resistance. In enzyme assays, AKR1Cs-IN-1 exhibits significant inhibitory activity with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM for AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. The compound shows excellent resensitizing effects in doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, effectively enhancing the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on breast cancer resistance.

AKR1C3-IN-4: potent, selective AKR1C3 inhibitor, IC50 = 0.56 μM, potential for CRPC research.

Alrestatin (AY-22284) is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in

Ponalrestat is an aldose reductase inhibitor.

<p>Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor.</p>

Acid Yellow 36 (Metanil Yellow) is an azo dye and a pH indicator. Acid Yellow 36 changes its color from red at pH 1.2 to yellow at pH 2.3.

<p>Sorbinil is an Aldose reductase inhibitor.</p>

<p>Methotrexate disodium is an tetrahydrofolate dehydrogenase inhibitor</p>

2-Chloro-1-(4-fluorobenzyl)benzimidazole is an inhibitor of aldose reductase (ALR2).

COH29 is an oral RNR-blocking thiazole that may reduce DNA synthesis and promote apoptosis, with potential cancer-treating properties.

Poliumoside: natural, inhibits glycation (IC50=4.6-25.7 μM) & aldose reductase (IC50=0.85 μM), with antioxidant, antibacterial & hemostatic properties.

EBPC is an inhibitor of aldose reductase.

<p>Pralatrexate (10-Propargyl-10-deazaaminopterin) is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate</p>

<p>Sodium aurothiomalate (Miochrysin) inhibits PKC-ι, TrxR; used as an anti-rheumatic and has anti-tumor properties.</p>

<p>Ethaselen (BBSKE) is an oral TrxR inhibitor with IC50 of 0.5 μM (human) and 0.35 μM (rat), targeting a selenocysteine site to fight NSCLC.</p>

Kopexil is a compound similar to minoxidil that promotes hair growthby inhibiting 5α-reductase and possibly activating potassium channel switches.

Tolrestat (AY-27773) is a potent inhibitor of aldose reductase (IC50 = 35 nM).

Zenarestat is an orally active aldose reductase inhibitor capable of ameliorating diabetic peripheral neuropathy in rats with type 2 diabetes.

AY 9944 inhibits DHCR7 enzyme (IC50=13 nM) and sterol isomerase, leading to hypocholesterolemia and 7DHC buildup.

Fidarestat (SNK 860),Aldose reductase inhibitor (IC50=26 nM). Targets AKR1B10 (33 μM) and V301L AKR1B10 (1.8 μM). Potential diabetes treatment.

SN34037, specific Aldo-keto reductase 1C3 (AKR1C3) inhibitor, inhibiting the cytotoxic activity of PR-104A, suitable for studying PR-104A-responsive leukaemia.

Risarestat (CT-112) is a potent aldose reductase inhibitor and thyroid hormone receptor (TR) antagonist for the treatment of hypoglycemia.

<p>Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity.</p>

Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide can be used in anticancer studies.

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

<p>Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is</p>

Zopolrestat (CP 73850) is a potent inhibitor of aldose reductase (IC50 = 3.1 nM).

Ranirestat (AS-3201) is an AR inhibitor with neuroprotective properties that improves peripheral nerve dysfunction in rats with advanced diabetic polyneuropathy

NSC 645827 is an inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), with an IC50 of 0.7 μM.

<p>RJG-2051 is a selective covalent inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), with an IC50 value of 13 nM. It interferes with the metabolism of substrates such as androgens, estrogens, and prostaglandins through AKR1C3. RJG-2051 holds potential for cancer research.</p>

(Rac)-Fidarestat ((Rac)-SNK 860) is the racemic form of Fidarestat, functioning as a potent inhibitor of the enzyme aldose reductase.